INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Seattle Genetics, Inc. Investors

BENSALEM, Pa.--(BUSINESS WIRE)--

Law Offices of Howard G. Smith announces an investigation on behalf of Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") SGEN investors concerning the Company and its officers' possible violations of federal securities laws.

Seattle Genetics is a biotechnology company that develops and commercializes targeted therapies for the treatment of cancer worldwide.

On December 27, 2016, Seattle Genetics disclosed that the U.S. Food and Drug Administration ("FDA") had placed a clinical hold or partial clinical hold on the Company's experimental cancer drug, vadastuximab talirine. The purpose of the hold, according to the FDA, is to evaluate the risk of hepatotoxicity. Seattle Genetics stated that six acute myeloid leukemia patients had been identified with liver toxicity and that four had died.

On this news, shares of Seattle Genetics fell over 16% on December 27, 2016.

If you purchased Seattle Genetics securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170124006564/en/